Donor T-Cells take on stubborn CMV in transplant patients
NCT ID NCT02210078
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This phase 2 trial tests whether immune cells from donors who have been exposed to CMV can treat persistent CMV infections in patients who have had a stem cell transplant. The study includes 49 participants with CMV that hasn't improved with standard antiviral drugs. The cells are given intravenously, and the goal is to clear the infection without needing additional doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor cytomegalovirus-specific cytotoxic T-lymphocytes (immune cells)
What this could lead to
If it works, this could offer a way to control CMV infections in patients with weakened immune systems after stem cell transplants.
What could go wrong
This is a small, early-phase trial with only 49 participants. The treatment may not work for everyone, and there are risks like graft-versus-host disease or the infection not clearing.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.